Antimicrobial peptides (AMPs) are short, cationic, amphiphilic molecules produced by a wide range of organisms, including bacteria, plants, invertebrates, and vertebrates. They play a crucial role in the innate immune system, helping to defend against pathogens by directly killing bacteria, fungi, viruses, and parasites. AMPs are found in various tissues and body fluids, such as the skin, mucosal surfaces, and immune cells. They can be constitutive or inducible, depending on the organism's need for defense. AMPs have diverse structural features, including α-helical, β-sheet, loop, and extended structures, and their functions are influenced by their sequence, charge, and secondary structure. AMPs exhibit antiviral activity by interacting with viral envelopes, blocking viral entry, or inhibiting viral replication. They can also block cell-to-cell spread of viruses by interfering with viral entry or syncytium formation. Some AMPs interact with specific cellular receptors, such as the chemokine receptor CXCR4, which is used by HIV-1 to enter T cells. Others interact with viral glycoproteins, such as HSV-2 glycoprotein B or HIV-1 gp120, to prevent viral entry. AMPs can also interact with the viral envelope or cellular membranes, leading to membrane destabilization or pore formation, which can result in viral inactivation. Antibacterial AMPs primarily act by interacting with the bacterial cell membrane, often through membrane permeabilization. They can also target intracellular processes, such as protein synthesis or DNA replication, leading to bacterial cell death. The structural requirements for antibacterial activity include a net positive charge, hydrophobicity, and flexibility, which allow the peptides to interact with bacterial membranes. The mode of action of antibacterial peptides can be either membrane-permeabilizing or non-membrane-permeabilizing, depending on the peptide's structure and the target cell. Antifungal and antiparasitic activities of AMPs are also well-documented, with many peptides showing broad-spectrum activity against fungi and parasites. The development of AMPs for clinical applications is an active area of research, with efforts focused on improving their stability, potency, and specificity. AMPs have shown promise as potential therapeutic agents due to their broad-spectrum activity, low toxicity, and ability to target a variety of pathogens. However, challenges remain in optimizing their use in clinical settings, including issues related to their stability, delivery, and resistance development. Overall, AMPs are important components of the innate immune system and have significant potential in the development of new antimicrobial therapies.Antimicrobial peptides (AMPs) are short, cationic, amphiphilic molecules produced by a wide range of organisms, including bacteria, plants, invertebrates, and vertebrates. They play a crucial role in the innate immune system, helping to defend against pathogens by directly killing bacteria, fungi, viruses, and parasites. AMPs are found in various tissues and body fluids, such as the skin, mucosal surfaces, and immune cells. They can be constitutive or inducible, depending on the organism's need for defense. AMPs have diverse structural features, including α-helical, β-sheet, loop, and extended structures, and their functions are influenced by their sequence, charge, and secondary structure. AMPs exhibit antiviral activity by interacting with viral envelopes, blocking viral entry, or inhibiting viral replication. They can also block cell-to-cell spread of viruses by interfering with viral entry or syncytium formation. Some AMPs interact with specific cellular receptors, such as the chemokine receptor CXCR4, which is used by HIV-1 to enter T cells. Others interact with viral glycoproteins, such as HSV-2 glycoprotein B or HIV-1 gp120, to prevent viral entry. AMPs can also interact with the viral envelope or cellular membranes, leading to membrane destabilization or pore formation, which can result in viral inactivation. Antibacterial AMPs primarily act by interacting with the bacterial cell membrane, often through membrane permeabilization. They can also target intracellular processes, such as protein synthesis or DNA replication, leading to bacterial cell death. The structural requirements for antibacterial activity include a net positive charge, hydrophobicity, and flexibility, which allow the peptides to interact with bacterial membranes. The mode of action of antibacterial peptides can be either membrane-permeabilizing or non-membrane-permeabilizing, depending on the peptide's structure and the target cell. Antifungal and antiparasitic activities of AMPs are also well-documented, with many peptides showing broad-spectrum activity against fungi and parasites. The development of AMPs for clinical applications is an active area of research, with efforts focused on improving their stability, potency, and specificity. AMPs have shown promise as potential therapeutic agents due to their broad-spectrum activity, low toxicity, and ability to target a variety of pathogens. However, challenges remain in optimizing their use in clinical settings, including issues related to their stability, delivery, and resistance development. Overall, AMPs are important components of the innate immune system and have significant potential in the development of new antimicrobial therapies.